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Background: The aim of this study was to develop a generalized in vitro-in vivo relationship 
(IVIVR) model based on in vitro dissolution profiles together with quantitative and qualitative 
composition of dosage formulations as covariates. Such a model would be of substantial aid 
in the early stages of development of a pharmaceutical formulation, when no in vivo results 
are yet available and it is impossible to create a classical in vitro-in vivo correlation (IVIVC)/
IVIVR.
Methods: Chemoinformatics software was used to compute the molecular descriptors of drug 
substances (ie, active pharmaceutical ingredients) and excipients. The data were collected from 
the literature. Artificial neural networks were used as the modeling tool. The training process 
was carried out using the 10-fold cross-validation technique.
Results: The database contained 93 formulations with 307 inputs initially, and was later limited 
to 28 in a course of sensitivity analysis. The four best models were introduced into the artificial 
neural network ensemble. Complete in vivo profiles were predicted accurately for 37.6% of 
the formulations.
Conclusion: It has been shown that artificial neural networks can be an effective predictive 
tool for constructing IVIVR in an integrated generalized model for various formulations. 
Because IVIVC/IVIVR is classically conducted for 2–4 formulations and with a single active 
pharmaceutical ingredient, the approach described here is unique in that it incorporates various 
active pharmaceutical ingredients and dosage forms into a single model. Thus, preliminary 
IVIVC/IVIVR can be available without in vivo data, which is impossible using current IVIVC/
IVIVR procedures.
Keywords: artificial neural networks, in vitro-in vivo, correlation, relationship, bioavailability, 
soft computing
Introduction
An efficient in vitro-in vivo correlation (IVIVC) model is a tool for predicting the 
in vivo bioavailability of a particular drug based on its in vitro data, and is simple to 
obtain using reproducible and inexpensive dissolution tests. This correlation enables 
the bioperformance of various dosage formulations to be evaluated without conducting 
animal or human studies. Applications of IVIVC include justification of biowaivers, 
post-approval scale-up changes,1 and establishing dissolution specifications. IVIVC is 
also used during the early stages of development of a dosage formulation, bringing in 
some degree of biorelevance to in vitro dissolution tests.2 The classical term, IVIVC, 
is often broadened to include the in vitro-in vivo relationship (IVIVR), indicating 
introduction of nonlinear modeling when classical linear IVIVC relationships are not 
sufficient or are not applicable.3
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Modeling based on artificial neural networks (ANNs) 
is a well established method.4 Although it requires vast 
computational power, it is very useful because of its self-
organizational properties and ability to incorporate many 
variables and relationships without a predefined model 
structure, unlike conventional statistical methods. In the 
case of IVIVR, these features allow inclusion of more 
variables than just the dissolution profile, such as formulation 
composition and manufacturing parameters when building 
a model, and enable direct evaluation of their influence on 
the in vivo response.
ANNs encompass a vast number of computational 
techniques which can imitate the human brain morphologically 
and functionally, and are capable of identifying hidden 
relationships between many variables. In practice, a neural 
network is a set of highly interconnected processing elements 
known as nodes (analogs of biological neurons), which store 
experimental knowledge by adjusting connection weights 
and make that knowledge available for use. An ANN is 
characterized by so-called architecture (arrangement of nodes 
and their connections), activation function, and training 
conditions. ANN architecture consists of an input and output 
layer, and one or more hidden layers. Relevant in this case 
is so-called supervised training, which is performed by 
presenting pre-existing task examples (the training data set) 
with known system responses to the input patterns. This is 
a crucial step for obtaining a well performing model able to 
predict output values for unknown patterns.4
Neural modeling is already well established in 
pharmaceutical science. In pharmaceutical technology, 
ANNs have been successfully applied for optimization 
of formulations5–8 and optimization of preparation 
technology.9–11 There are also numerous applications of 
ANNs in pharmacokinetics.12–17 Finally, neural modeling 
for IVIVC has been studied.18–21 All these applications of 
ANNs for IVIVC use these networks as a nonlinear mapping 
tool for in vitro and in vivo profiles, and have been limited 
to single drugs and/or formulations. So far, to the authors’ 
knowledge, there has been no attempt to create a universal 
model encompassing different formulations and different 
active pharmaceutical ingredients.
The aim of this study was to investigate the concept of a 
generalized IVIVR model, introducing, in addition to in vitro 
and in vivo profiles, chemoinformatics software providing 
physicochemical properties and structural data about drug 
substances and excipients. Use of chemoinformatics ensures 
the ability of the model to predict the bioavailability of 
various drugs in different dosage formulations. Such a model 
might be used earlier than classical IVIVC, given that the 
latter requires biological data as the dependent variable for 
the correlation.
Materials and methods
Knowledge database
A knowledge database was acquired from the published 
literature. Articles concerning bioavailability and dissolution 
studies of various formulations were scanned, and the 
relevant data was extracted upon following conditions:
•	 Complete details on qualitative and quantitative 
composition of immediate-release or modified-release 
formulations, as well as dissolution tests and bioavailability 
studies results
•	 Bioavailability studies were carried out in humans, with 
tablets or capsules administered orally
•	 Release modification was based on the matrix system
•	 The active pharmaceutical ingredient was a small chemical 
molecule (with peptides and antibodies discarded)
•	 Dissolution tests carried out using USP apparatus 
I or II.
The data records were characterized by the following 
variables:
•	 Formulation characteristics, ie, type, and qualitative and 
quantitative composition
•	 In vitro dissolution profile
•	 In vivo pharmacokinetic profile
•	 In vitro and in vivo assay conditions.
Formulation
The formulation type was encoded as two binary parameters. 
The first denoted immediate-release versus modified-release 
formulation, encoded as 0 and 1, respectively, and the second 
denoted tablet versus capsule, respectively.
Numerical description of the qualitative composition 
of the formulation was based on chemoinformatics tools. 
Each ingredient of the formulation was incorporated into 
the database as a set of molecular descriptors computed with 
Marvin22 calculator plugins (ChemAxon, Budapest, Hungary) 
and classified into three groups, ie, active pharmaceutical 
ingredient, polymeric release-modifying excipients, and 
nonpolymeric release-modifying excipients.
Computation of molecular descriptors for the active 
pharmaceutical ingredient and nonpolymeric excipients was 
straightforward with use of standard software settings. Prior 
to computation of molecular descriptors, three-dimensional 
optimization of the molecules was performed using the 
gradient method with Marvin software.22
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For polymeric release-modifying excipients, direct use 
of chemoinformatics software is difficult or sometimes 
 impossible. This is mainly due to input limitations on com-
pound size in the chemoinformatics software. To overcome 
this obstacle, polymers were presented as dimers with hydro-
gen instead of the chain fragment on one side and hydroxyl on 
the other. For cellulose derivatives, various substitution com-
binations were taken into account and several sets of descrip-
tors were computed for different substitution variations, which 
were averaged according to the molar substitution ratio for 
each group. Calculations for hydroxypropylmethylcellulose 
were presented schematically in Figure 1.
Agents other than polymers still influencing the drug 
release rate, such as triglycerides, and citric or stearic acid, 
were classified into a third group of nonpolymeric excipients. 
In total, 250 descriptors were introduced into the native input 
vector. An applied schema for merging and weight averaging 
is shown in Figure 2. Quantitative composition was simply 
expressed as the weight percentages for each compound 
along with the dose of the active pharmaceutical ingredient 
expressed both as a percentage and in milligrams.
In vitro and in vivo profiles
In order to ensure compatibility of the data, the pharmacoki-
netic and dissolution profiles were preprocessed. For pharma-
cokinetic profiles, the concentration units were recalculated 
if necessary and expressed in ng/mL. There was no such 
problem for the in vitro profiles because their values were 
always available in percentages of the total drug amount in 
the formulation. For both the in vitro and in vivo profiles, the 
average values reported in the published literature were used. 
Most of the data was extracted from the graphs by g3data 
software using a simple point-and-click procedure. Because 
of the manual nature of the above procedure, another member 
of the team rescanned approximately 5% of the randomly 
chosen profiles for validation purposes. All time points for 
the in vitro and in vivo profiles were expressed in hours. The 
time scale for the pharmacokinetic profiles was 0–120 hours 
and for dissolution profiles was 0–24 hours. There were up 
to 18 time points available for the dissolution profiles; for 
those with a smaller number of points, the remaining points 
were created artificially with time up to 24 hours and pla-
teau values. The latter was the result of linear extrapolation 
between the last value present and the maximum possible 
amount of active pharmaceutical ingredient released (100%) 
at the time endpoint of 24 hours.
Assay conditions
For the in vitro dissolution profiles, there was information 
provided about the volume and pH of the medium, together 
with the paddle or basket rotation speed (rpm). Sodium lauryl 
sulfate concentration was also introduced as a variable. For 
pharmacokinetic profiles, in order to ensure eligibility of 
the maximum number of papers, in vivo characteristics was 
limited to information about whether the assay was performed 
in a fasted or fed state.
neural modeling
The neural models of IVIVR were designed to predict whole 
plasma concentration-time profiles based on dissolution 
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Figure 1 Schematic calculation of descriptors set encoding hypromellose.
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curves and the composition of the formulation, as well as data 
on the conditions of the in vivo and in vitro studies.
All models were multiple-input-single-output type with 
the natural logarithm of plasma concentration as the output 
vector. The input vector consisted of the quantitative and 
qualitative description of the formulation as described 
above together with the in vitro dissolution profile, in vivo 
sampling time, and conditions of the in vitro and in vivo 
assays (Figure 3).
Multilayer perceptrons with a back-propagation learning 
algorithm were applied. The following activation functions 
were implemented: linear, logistic, hyperbolic tangent, and a 
combination of logarithmic functions known as “fsr”.23 The 
ANN architectures varied from one to seven hidden layers. 
In addition to multilayer perceptrons, neurofuzzy systems of 
the simplest Mamdani type were employed, with 5–100 nodes 
in the hidden layer. In order to match nonlinear activation 
function domains, the data were scaled linearly using output 
ranges of ,0.2, 0.8., and ,−0.8, 0.8., respectively. 
A noise addition was performed with amplitude ±5% of 
the original values and a four times larger number than 
the original records. The latter procedure is a well known 
technique which is used to improve the generalizability of 
neural models.4 Numerous modifications of the classical 
back-propagation algorithm were used, as follows:
•	 Momentum technique with a momentum factor of 0.3
•	 Delta-bar-delta algorithm with an initial learning factor 
of 0.65
•	 Jog-of-weights technique designed to avoid becoming 
stuck in the local minima of the cost function; a simple 
noise addition to the weights where the ANN was not 
improving its efficiency during 100,000 epochs (the 
patience criterion).
In total, considering two types of scaling and whether or not 
noise data were used, 336 types of neural networks were trained 
and tested. Training was conducted up to numerous predefined 
steps (50,000, 100,000, and up to 10,000,000 iterations), after 
which training and generalization errors were observed. The 
error measures were root mean squared error (equation 1) and 
normalized root mean squared error (equation 2)
 RMSE
pred obs
n
i i
i
n
= =
−( )∑ 2
1  (1)
where obs
i
 is the observed value, pred
i
 is the predicted value, 
and n is the total number of records.
 NRMSE
RMSE
MAX MINobs obs
=
−
⋅100% (2)
where RMSE is the root mean squared error, MAX
obs
 is the 
maximum value of the observed results, and MIN
obs
 is the 
minimum value of the observed results.
Dimers
eg.:
(Methoxy-GIc)2
Polymer no 1
eg. HPMC
Non-polimeric excipient no 1
eg. triglyceride
Non-polimeric excipient no 2
Toral : 250 inputs
 InputAveraged descriptorDescriptor
Polymer no 2
(Hydroxypropoxy-GIc)2
(Anhydro-GIc)2
API 96 inputs
82 inputs
72 inputs
Figure 2 Chemoinformatic description of the excipients included into the native input vector.
Quantitative composition
ANN
InC in vivo
(at t in vivo)
Qualitative composition
In vitro studies conditions
In vivo studies conditions
Complete in vitro profile
t in vivo (single input)
Figure 3 General structure of artificial neural network models.
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Two major modes of ANN training were used, ie, 
sensitivity analysis on the whole dataset and a 10-fold cross-
validation technique for assessment of generalizability. 
These modes were used in their interplay in order to provide 
the minimum input vector, ie, the set of crucial variables. 
Optimization of ANN architecture was derived at the same 
time. A detailed description of this approach has been 
presented elsewhere.24
An extended 10-fold cross-validation scheme was 
used, whereby whole formulations were treated as units for 
construction of pairs of train/test datasets. This was to ensure 
that the all information about a particular formulation was 
either in the test or the train dataset, in order to simulate the 
practical application of the system, ie, to predict the actual 
bioperformance of the formulation.
Sensitivity analysis was done using the method described 
by Z
.
urada et al,25 with some modifications24 to enable 
knowledge-based selection of crucial variables and obtain 
collective results from the set of best trained ANNs.
ANN ensembles (“expert committees”) were prepared in 
order to enhance the predictive ability of the models obtained. 
These higher order models were constructed from the best 
ANNs identified. Their total output was computed as the 
average of the outputs for the ANNs chosen as members of 
the ensemble.
Three rankings were prepared for a clear description of 
the predictability of the model, ie, ability to predict the whole 
in vivo profile, ability to predict the elimination phase, and 
ability to predict the absorption phase. The absorption phase and 
elimination phase were simply chosen as the ranges from t = 0 to 
t
max
 and from t
max
 to the last time point, respectively, thus being 
the ascending and descending parts of the pharmacokinetic 
curve. Successful prediction was confirmed if the normalized 
root mean squared error did not exceed 20%.
hardware and software environment
The neural analysis was performed using own-written simulator 
Nets2010 and numerous applications for data preprocessing,24 
all working in the Linux environment. Literature in graphic 
form was digitalized using g3data version 1.5.2.26 Formulation 
ingredients were encoded by Marvin version 5.3.8 plugins.22 
All computations were performed on 29 PC workstations (116 
cores). The total number of neural networks trained and tested 
was approximately 8000.
Results
Our search identified 93 formulations in the literature database. 
It contained a description of 13 active pharmaceutical 
ingredients, ie, levosimendan,27,28 ritonavir,29 danazol,30 
metoprolol,31–34 griseofulvin,35 diltiazem,36 propranolol,32 
alprazolam,37 ketoprofen,38 diclofenac,39 carbamazepine,40 
ibuprofen,41,42 and theophylline.43 In total, the database 
yielded 1067 data records. Initially, there were 307 inputs of 
the neural model (Table 1) describing active pharmaceutical 
ingredients, excipients, and assay conditions.
Sensitivity analysis showed the significance of variables 
describing the type of drug formulation (tablet or capsule, 
immediate-release/modified-release), bioavailability and 
dissolution study conditions, and quantitative composition 
(Figure 4). The model was less sensitive to inputs covering 
the dissolution profile. The most important molecular 
descriptors were active pharmaceutical ingredient, with 
polymeric excipients lower in the ranking and descriptors 
for nonpolymeric excipients being discarded.
As a result of the input vector reduction procedure, 
28 governing variables were chosen (Table 2), among which 
were 13 molecular descriptors of active pharmaceutical ingredi-
ents and three descriptors of polymers. Only two sampling times 
remained for the in vitro profile, resulting in four inputs.
Table 1 General description of the native input vector
Input number Information encoded
1 Modified release: yes (1), no (0)
2 Dosage form: tablets (0), capsules (1)
3 Amount of polymers (%); for IR formulations (0)
4 Amount of nonpolymeric excipients (%); for IR 
formulations (0)
5 Amount of API (%); for IR formulations (100%)
6 Dose of API in formulation (mg)
7 ph value of medium in dissolution test
8 Volume of dissolution medium (mL)
9 Presence of SLS in dissolution medium: yes (1), 
no (0)
10 Rotation speed (rpm) in paddle or basket 
method of dissolution test
11 Fasting conditions in bioavailability study: yes (0), 
no (1)
12–107 Set of molecular descriptors of API calculated by 
chemoinformatic software
108–189 Set of averaged molecular descriptors of 
polymers; for IR formulations (0)
190–271 Set of averaged molecular descriptors of 
nonpolymeric excipients; for IR formulations (0)
272–289 Dissolution profile – percent of API released into 
medium in each sampling time
290–306 Sampling times of dissolution test (h) 
corresponding with % of API released
307 A sampling time of in vivo study tin vivo (h)
OUT natural logarithm of API plasma concentration 
[ng/mL] at tin vivo
Abbreviations: API, active pharmaceutical ingredient; IR, immediate-release; SLS, 
sodium lauryl sulfate.
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Using the trial and error method, various combinations 
of both multilayer perceptron nets and fuzzy neural networks 
were formed into the ANN ensembles and tested for the 
lowest generalization root mean squared error. Finally, four 
ANNs were combined (Table 3), with a collective root mean 
squared error of 1.05. The preferred activation functions were 
fsr and hyperbolic tangent. Fuzzy networks, although capable 
of predicting profiles for certain formulations, proved to be 
insufficient for generalization of the different formulations. 
The number of hidden layers varied from two to seven, within 
the total number of nodes from 12 to 142. Such diversity 
shows that different problems (different dosage formulations, 
model drugs, orders of magnitude of plasma concentrations) 
were better solved with different ANN architecture, so it is 
understandable that the collective root mean squared error 
was lower than for each ANN apart.
Charts with plasma profiles predicted by an expert 
committee and profiles observed in the clinical trials were 
plotted (Figure 5). According to the aforementioned criterion 
of normalized root mean squared error , 20%, a ranking 
was created which showed successful prediction of the whole 
profile in 37.6% of the formulations. The elimination part 
of the curve was appropriately predicted for 49.5% of the 
formulations, whereas absorption was predicted for only 
19.4%. Such a tendency for better predictability of the part 
of the in vivo curve covering the elimination phase over the 
one describing the absorption process could be explained 
by the observed higher sensitivity of the model to molecular 
descriptors of the active pharmaceutical ingredient and 
lower sensitivity to the inputs responsible for the excipients 
and the dissolution profile. The process of elimination of 
a drug involves elimination kinetics, metabolism, and/or 
redistribution, all of which depend on the physicochemical 
properties of the active pharmaceutical ingredient rather than 
the drug formulation. On the other hand, the formulation 
and its influence on the dissolution rate of the active 
pharmaceutical ingredient has a great impact on the rate of 
drug absorption, especially in the case of modified-release 
formulations.
Discussion
The foundations of the IVIVR are that the in vitro release 
profile for an active pharmaceutical ingredient should reflect 
basic release/dissolution processes, which are at least in part 
responsible for the bioavailability of the active ingredient. 
The low affinity of ANN models for the dissolution profile 
suggests that the in vitro data available in the database we 
collected did not correlate well with the in vivo profiles. 
A further numerical experiment was performed in order 
to investigate this problem. The original model based on 
28 inputs was enhanced with the whole dissolution profile, 
despite the previously described sensitivity analysis results. 
As a result, 58 input-based models were created, trained, and 
tested according to the methodology described earlier. ANN 
ensembles for a model based on these 58 inputs were built on 
the same architecture as that used for the model of 28 inputs. 
Relative importance
Formulation type
Amount of release-modifying excipients (%)
Amount of API (%)
Dose (mg)
In vitro study conditions
In vivo study conditions
Molecular descriptors of API
Molecular descriptors of polymeric excipients
Molecular descriptors of nonpolymeric excipients
Dissolution profile
In vivo sampling time
0% 1% 2% 3% 4% 5% 6% 7% 8% 9% 10%
Figure 4 Results of sensitivity analysis for the most important 28 inputs, with relative importance computed in the context of the native dataset.
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The resulting generalization root mean squared error was 
found to be 1.51, confirming the relatively low correlation 
of the in vitro and in vivo profiles in the database analyzed. 
An increase in error might be associated with the well known 
“curse of dimensionality”, resulting from the enlarged input 
vector, but it is noteworthy that all the in vitro assays were 
carried out using USP apparatus I or II. These methods are 
still the standard for dissolution testing, so the data sources 
were available at a level only allowing work such as that 
presented here. Despite standardization of the methods used, 
USP apparatus I and II mimic in vivo conditions poorly, 
sometimes not even achieving sink conditions. Our modeling 
results presented here are indirect proof of this.
Another issue is the formulation description used, ie, 
chemical structure only, which was included together with 
abstract classification as immediate-release or modified-
release. This is surely inadequate for thorough description of 
a pharmaceutical formulation, and some physical parameters 
should also be included, such as dimensions, hardness, 
and particle size of the excipients. Unfortunately, no such 
information was available in the papers selected, and if any 
such variables were included, they were so scarce that they 
were not useful for systematic quantitative analysis. A similar 
dilemma of how to provide a database representative 
enough to build the model was encountered for the in vivo 
profiles. Their description was limited only to the fast/fed 
state because this information was available by default. 
As a consequence, the model was built on average data, 
without taking into account any intrasubject and intersubject 
variability nor mentioning any demographic data. An attempt 
to introduce the above-mentioned data would be the next 
stage of research.
The above considerations of model performance are 
based on the potential for extrapolation, which is not perfect. 
It is important to remember here that the above-mentioned 
generalization errors are the result of the 10-fold cross-
validation procedure, which is a statistical technique and 
a derivative of bootstrapping methods. The 10-fold cross-
validation procedure tests the predictive ability of the model 
according to the whole available database, yet with use of 
the external data, excluded from the training process of the 
model. Here, external data are a result of the resampling 
technique applied to the database, ie, 10-fold cross-validation. 
Therefore, the results presented in the Figure 5 reflect the real 
situation, where the model is faced with the task of predicting 
bioperformance of a completely unknown formulation based 
solely on its in vitro and chemoinformatic characteristics.
Table 2 Input vector reduced to 28 governing variables
Original input 
numbera
Information encoded
Type of dosage form
2 Dosage form: tablets (0), capsules (1)
Quantitative composition
3 Amount of polymers (%); for IR formulations (0)
4 Amount of nonpolymeric excipients (%); for IR 
formulations (0)
5 Amount of API (%); for IR formulations (100%)
6 Dose of API in formulation (mg)
In vitro test conditions
8 Volume of dissolution medium (mL)
In vivo assay conditions
11 Fasting conditions in bioavailability study (0/1)
Molecular descriptors of API
14 Aromatic atom count
22 hetero ring count
23 heteroaliphatic ring count
30 Largest ring size
40 Balaban index
44 Dreiding energy
48 Maximal projection radius
57 Atom count
58 logD at ph 1
75 Acceptor count
104 hydrogen bond donor count at ph 12
105 hydrogen bond donor count at ph 13
106 hydrogen bond donor count at ph 14
Molecular descriptors of polymer
130 Maximal projection area
131 Maximal projection radius
151 logD at ph 10
Dissolution profile
272 Dissolution profile: percent of API released in 
sampling time t1
288 Dissolution profile: percent of API released in 
sampling time t17
290 Sampling time of dissolution test [h] in t1
306 Sampling time of dissolution test [h] in t17
In vivo assay
307 One sampling time of in vivo study tin vivo [h]
OUT natural logarithm of API plasma concentration 
[ng/mL] at tin vivo
Note: anumbers refer to the original input vector presented in Table 1.
Abbreviation: API, active pharmaceutical ingredient.
Table 3 Architecture of Anns selected for expert committee 
and their generalization errors
ANN 
number
Nodes in hidden 
layers 1–7 (n)
Activation 
function
Scaling 
range
RMSE
h1 h2 h3 h4 h6 h7
1 60 40 20 10 8 4 fsr 0.2; 0.8 1.21
2 7 5 – – – – fsr 0.2; 0.8 1.28
3 60 20 10 8 4 – tanh 0.2; 0.8 1.30
4 7 5 3 2 – – tanh −0.8; 0.8 1.38
RMSE for the whole ensemble 1.05
Abbreviations: ANN, artificial neural networks; h, hidden layer; RMSE, root mean 
squared error.
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Further, in order to demonstrate the real application of 
the system, a new dataset was introduced, including data 
from the recent study published by Zaid et al concerning 
the in vitro-in vivo characteristics of montelukast,44 which 
is a completely unknown structure in the system. Prediction 
of its behavior is presented in Figure 6. It is not a perfect 
representation of the pharmacokinetic profile measured 
in vivo (normalized root mean squared error 23%), but 
ANNs were able to predict the general characteristics 
of the pharmacokinetic profile for montelukast from the 
immediate-release formulation, ie, t
max
 (overestimated by 
1.5 hours) and the last measured concentration. Moreover, 
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Form: MR tablet
API: ketoprofen
NRMSE = 12.34%
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API: theophylline
NRMSE = 11.32%
Form: IR tablet
API: metoprolol
A
B
C
PRED
2 4 6 8 10 12 14 16 18
Figure 5 Examples of in vivo profile predictions.
Abbreviations: API, active pharmaceutical ingredient; IR, immediate release formulation; MR, modified release formulation; NRMSE, normalized root mean squared error; 
OBS, observed profile; PRED, profile predicted by the neural model.
1200
C
o
n
ce
n
tr
at
io
n
 [
n
g
/m
L
]
1000
800
600
400
200
0
0 5 10
Time [h]
15 20 25
NRMSE = 23.05%
Form: IR tablet
API: montelukast
OBS
PRED
Figure 6 Example of in vivo profile prediction for the new test dataset introduced after the model development phase.
Abbreviations: API, active pharmaceutical ingredient; IR, immediate release formulation; NRMSE, normalized root mean squared error; OBS, observed profile; PRED, 
profile predicted by the neural model.
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ANNs correctly predicted that the concentration of 
montelukast rises rapidly after administration of the drug, 
thus the first point measured is around 400 ng/mL. This 
result is an example of extrapolation beyond the known 
database, and this can be illustrated by comparison of the 
values for the Dreiding energy parameter, ie, the maximum 
value for the database is 137.26, whereas for montelukast 
it was estimated at 357.48. The numbers quoted above are 
confirmation of the long-range extrapolation performed by 
the neural model, and although not entirely precise, are still 
reasonable and within the range of concentrations measured 
in vivo (Figure 6).
Conclusion
While clinical trials have remained time-consuming and 
expensive despite significant technological improvements 
over the years, development of information technology has 
increased rapidly and provides inexpensive hardware with 
immense computation power as well as superior software. 
Therefore, it seems reasonable to use its potential in the 
field of pharmaceutical research. IVIVC/IVIVR is now a 
standard and necessary tool in the pharmaceutical industry 
and reduces the cost of clinical trials, but in its classical 
form has limited applications. Specifically, the classical 
IVIVC/IVIVR approach involves 2–4 formulations with 
a single active pharmaceutical ingredient and requires in 
vivo data along with in vitro release profiles. Therefore, 
the procedure is limited in its ability to identify a 
mathematical function describing two sets of data (in 
vivo versus in vitro), and it is obligatory to have both 
these datasets.
Any extension of the current capabilities of IVIVC/
IVIVR models would be benef icial, providing more 
scientific justif ication for decision-making in the early 
stages of drug development. The model presented here 
provides such an extension by introducing the complex 
relationships between active pharmaceutical ingredients 
and excipients, and mapping the in vitro profile directly 
to the in vivo profile for a particular drug formulation. 
The input of the system does not require an in vivo 
profile, so allows an IVIVR to be created at an earlier 
stage of drug development than does classical IVIVC/
IVIVR.
In this study, neural modeling was demonstrated to be 
capable of handling complex problems, such as building an 
IVIVR model using a generalized approach not identified 
in the published literature. A detailed methodology was 
established which is suitable for further extension of the 
database, which is a crucial task in future development of 
IVIVR for real-life application. It was a first step towards 
the development of an integrated IVIVC/IVIVR system 
in silico, which might be used in the early stages of drug 
development to assess the effects of formulation parameters 
on the biological properties of a given drug. Such an empirical 
modeling-based system would be an enhancement, but 
certainly not a replacement, for current systems based on 
mechanistic modeling. A major advantage of such neural 
models is that they can integrate information easily, thus 
enhancing the models currently used, and provide more 
detailed information on formulation characteristics and a 
better description of test subjects if the relevant data were 
provided in the future.
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